anti-PD-L1 mAbs

Anti-PD-L1 monoclonal antibodies (mAbs) are a class of cancer immunotherapies designed to block the interaction between programmed death-ligand 1 (PD-L1) on tumor cells (or tumor-infiltrating immune cells) and programmed cell death protein 1 (PD-1) on T cells. By inhibiting this immune checkpoint pathway, anti-PD-L1 mAbs prevent the inhibitory signals that suppress T-cell activation, thereby restoring and enhancing the host's anti-tumor immune response. Several anti-PD-L1 mAbs, such as atezolizumab, avelumab, and durvalumab, have been approved for various oncology indications, including non-small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer.

Other names

PD-L1 inhibitorsPD-L-1 inhibitorsPD-L 1 inhibitorsPD-L1 monoclonal antibodiesPD-L-1 monoclonal antibodiesPD-L 1 monoclonal antibodiesanti-PD-L1 mAbsanti-PD-L-1 mAbsanti-PD-L 1 mAbsanti-PD-L1 monoclonal antibodiesanti-PD-L-1 monoclonal antibodiesanti-PD-L 1 monoclonal antibodies